| 000 | 01837 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517052613.0 | ||
| 264 | 0 | _c20160712 | |
| 008 | 201607s 0 0 eng d | ||
| 022 | _a1177-8881 | ||
| 024 | 7 |
_a10.2147/DDDT.S86558 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKumari, Namita | |
| 245 | 0 | 0 |
_aInhibition of HIV-1 by curcumin A, a novel curcumin analog. _h[electronic resource] |
| 260 |
_bDrug design, development and therapy _c2015 |
||
| 300 |
_a5051-60 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnti-HIV Agents _xchemical synthesis |
| 650 | 0 | 4 |
_aCell Cycle Checkpoints _xdrug effects |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aCurcumin _xanalogs & derivatives |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Stability |
| 650 | 0 | 4 | _aEnzyme Induction |
| 650 | 0 | 4 |
_aGene Expression Regulation, Viral _xdrug effects |
| 650 | 0 | 4 |
_aHIV Reverse Transcriptase _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aHIV-1 _xdrug effects |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 |
_aHeme Oxygenase-1 _xbiosynthesis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aReverse Transcriptase Inhibitors _xchemistry |
| 650 | 0 | 4 |
_aT-Lymphocytes _xdrug effects |
| 650 | 0 | 4 | _aTransfection |
| 650 | 0 | 4 |
_aVirus Replication _xdrug effects |
| 700 | 1 | _aKulkarni, Amol A | |
| 700 | 1 | _aLin, Xionghao | |
| 700 | 1 | _aMcLean, Charlee | |
| 700 | 1 | _aAmmosova, Tatiana | |
| 700 | 1 | _aIvanov, Andrey | |
| 700 | 1 | _aHipolito, Maria | |
| 700 | 1 | _aNekhai, Sergei | |
| 700 | 1 | _aNwulia, Evaristus | |
| 773 | 0 |
_tDrug design, development and therapy _gvol. 9 _gp. 5051-60 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2147/DDDT.S86558 _zAvailable from publisher's website |
| 999 |
_c25257480 _d25257480 |
||